Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Endocr Relat Cancer. 2015 Oct;22(5):R279–R300. doi: 10.1530/ERC-15-0355

Figure 3. Higher expression of AGO2 is statistically associated with decreased relapse-free survival in all breast cancer and in patients whose primary tumors are ERα+/PR+.

Figure 3

The Kaplan-Meier plots of AGO2 expression in breast tumors with breast cancer survival were generated using http://kmplot.com/analysis/index.php?p=service (Gyorffy, et al. 2010). A) All breast tumors, n = 3557; B) ERα+/PR+, n = 701.